Treatment of pituitary neoplasms with temozolomide: A review

Cancer

Volumn 117, Issue 17, 2011, Pages 4101-4102

  Marucci, Gianluca ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

DRUG EFFICACY; GENE SILENCING; GENOTOXICITY; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; LETTER; PITUITARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; TREATMENT RESPONSE;

ADENOMA; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA; DACARBAZINE; HUMANS; PITUITARY NEOPLASMS;

EID: 80051920329     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26000     Document Type: Letter

References (5)

1. Syro LV, Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer. 2011; 117: 454-462.
2. Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R,. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary. 2010; 13: 367-379.
3. Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010; 95: 4592-4599.
4. Riemenschneider MJ, Hegi ME, Reifenberger G,. MGMT promoter methylation in malignant gliomas. Target Oncol. 2010; 5: 161-165.
5. Scheithauer BW, Gaffey TA, Lloyd RV, et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery. 2006; 59: 341-353. (Pubitemid 44325877)